The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1′ ol]-2-methyl-3-hydroxypyridin-4-one in the rat

Clinical pharmacokinetics; concepts and applications

1989 • 2,266 citations

ANGIOTENSIN-CONVERTING ENZYME AND THE COUGH REFLEX

1987 • 744 citations

Lipid Solubility and Drug Penetration of the Blood Brain Barrier

1974 • 372 citations

Clinical Pharmacokinetics: Concepts and Applications

1989 • 276 citations

The development of iron chelators for clinical use

1995 • 231 citations

Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential

1993 • 212 citations

Aluminium and the risk for alzheimer's disease

1995 • 193 citations

Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients

1990 • 166 citations

The Development of Iron Chelators for Clinical Use

1993 • 144 citations

Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one

1990 • 135 citations

2 The development of iron chelating drugs

1989 • 129 citations

Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice [see comments]

1990 • 101 citations

Aluminum Toxicity in Patients with Chronic Renal Failure

1993 • 77 citations

A comparison of the iron-clearing properties of 1,2-dimethyl-3- hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine

1992 • 75 citations

Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia

1991 • 61 citations

Antipyrine as a dialyzable reference to correct differences in efficiency among and within sampling devices during in vivo microdialysis

1992 • 58 citations

Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo

1993 • 57 citations

Evaluation of potential aluminum chelators in vitro by aluminum solubilization ability, aluminum mobilization from transferrin and the octanol/aqueous distribution of the chelators and their complexes with aluminum.

1991 • 52 citations

Dissimilar Aluminum and Gallium Permeation of the Blood‐Brain Barrier Demonstrated by In Vivo Microdialysis

1992 • 48 citations

Ultrafiltration studies in vitro of serum aluminum in dialysis patients after deferoxamine chelation therapy.

1985 • 45 citations

4-trimethylammonium antipyrine: A quaternary ammonium nonradionuclide marker for blood-brain barrier integrity during in vivo microdialysis

1992 • 38 citations

Deferoxamine as a Chelating Agent

1971 • 36 citations

Evidence for energy-dependent transport of aluminum out of brain extracellular fluid

1995 • 35 citations

Mean residence time in peripheral tissue

1987 • 20 citations

Influence of lipophilicity on the bioavailability and disposition of orally active 3-hydroxypyridin-4-one metal chelators.

1995 • 20 citations

Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases

1993 • 17 citations

Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94.

1993 • 12 citations

The pharmacokinetics of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rats.

1992 • 5 citations

HPLC Quantitation of a Very Hydrophilic 3-Hydroxypyridin-4-one Chelator Using a Simple Separation Procedure and the Baseline File Subtraction Method

1996 • 3 citations